S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80

Kintara Therapeutics Stock Forecast, Price & News

-0.01 (-4.02%)
(As of 07/6/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
1.26 million shs
Average Volume
4.75 million shs
Market Capitalization
$15.64 million
P/E Ratio
Dividend Yield
Price Target

Kintara Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
1,436.1% Upside
$3.67 Price Target
Short Interest
0.65% of Shares Sold Short
Dividend Strength
News Sentiment
Insider Trading
Proj. Earnings Growth
From ($0.51) to $0.03 Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.68 out of 5 stars

Medical Sector

844th out of 1,433 stocks

Pharmaceutical Preparations Industry

425th out of 683 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive KTRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kintara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Kintara Therapeutics logo

About Kintara Therapeutics (NASDAQ:KTRA) Stock

Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.

KTRA Stock News Headlines

Kintara in Danger
7 Penny Stocks With 10x Potential This Year
KTRA: A Farewell to GBM
Kintara Therapeutics GAAP EPS of -$0.12 beats by $0.05
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
4 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
($0.13) per share


Free Float
Market Cap
$15.64 million
Not Optionable

Kintara Therapeutics Frequently Asked Questions

Should I buy or sell Kintara Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kintara Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Kintara Therapeutics stock.
View analyst ratings for Kintara Therapeutics
or view top-rated stocks.

What is Kintara Therapeutics' stock price forecast for 2022?

4 Wall Street research analysts have issued 12-month price objectives for Kintara Therapeutics' stock. Their KTRA stock forecasts range from $3.00 to $5.00. On average, they predict Kintara Therapeutics' share price to reach $3.67 in the next twelve months. This suggests a possible upside of 1,436.1% from the stock's current price.
View analysts' price targets for Kintara Therapeutics
or view top-rated stocks among Wall Street analysts.

How has Kintara Therapeutics' stock price performed in 2022?

Kintara Therapeutics' stock was trading at $0.51 at the start of the year. Since then, KTRA shares have decreased by 53.2% and is now trading at $0.2387.
View the best growth stocks for 2022 here

When is Kintara Therapeutics' next earnings date?

Kintara Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, October 5th 2022.
View our earnings forecast for Kintara Therapeutics

How were Kintara Therapeutics' earnings last quarter?

Kintara Therapeutics, Inc. (NASDAQ:KTRA) announced its quarterly earnings data on Friday, May, 13th. The company reported ($0.11) EPS for the quarter, hitting analysts' consensus estimates of ($0.11).
View Kintara Therapeutics' earnings history

When did Kintara Therapeutics' stock split? How did Kintara Therapeutics' stock split work?

Shares of Kintara Therapeutics reverse split on the morning of Wednesday, May 8th 2019. The 1-10 reverse split was announced on Tuesday, May 7th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 7th 2019. An investor that had 100 shares of Kintara Therapeutics stock prior to the reverse split would have 10 shares after the split.

Who are Kintara Therapeutics' key executives?

Kintara Therapeutics' management team includes the following people:
  • Mr. Robert E. Hoffman C.P.A., CPA, Pres, CEO & Chairman (Age 56, Pay $95k)
  • Mr. Scott Praill B.Sc., C.P.A., CA, CPA, BSc, CFO & Sec. (Age 55, Pay $369.81k)
  • Mr. Jeffrey A. Bacha B.Sc., M.B.A., Founder (Age 54)
  • Dr. Dennis M. Brown B.Sc., M.A., Ph.D., Co-Founder & Chief Scientific Officer (Age 72)
  • Mr. Greg A. Johnson, Acting Head of Operations

What other stocks do shareholders of Kintara Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kintara Therapeutics investors own include Ampio Pharmaceuticals (AMPE), Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), (DMPI), Fortress Biotech (FBIO), Immunic (IMUX), Miragen Therapeutics (MGEN), Palatin Technologies (PTN), Rigel Pharmaceuticals (RIGL) and Trevena (TRVN).

What is Kintara Therapeutics' stock symbol?

Kintara Therapeutics trades on the NASDAQ under the ticker symbol "KTRA."

How do I buy shares of Kintara Therapeutics?

Shares of KTRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kintara Therapeutics' stock price today?

One share of KTRA stock can currently be purchased for approximately $0.24.

How much money does Kintara Therapeutics make?

Kintara Therapeutics (NASDAQ:KTRA) has a market capitalization of $15.64 million. The company earns $-38,300,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis.

How many employees does Kintara Therapeutics have?

Kintara Therapeutics employs 4 workers across the globe.

How can I contact Kintara Therapeutics?

Kintara Therapeutics' mailing address is 12707 HIGH BLUFF DR. SUITE 200, SAN DIEGO CA, 92130. The official website for Kintara Therapeutics is www.kintara.com. The company can be reached via phone at (858) 350-4364, via email at ir@delmarpharma.com, or via fax at 604-608-5685.

This page (NASDAQ:KTRA) was last updated on 7/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.